The Advisory Board Company to Present at the Stifel Nicolaus 2011 Healthcare Conference

WASHINGTON, Sept. 2, 2011 /PRNewswire/ -- The Advisory Board Company (NASDAQ: ABCO) announced today that it will participate in the upcoming Stifel Nicolaus 2011 Healthcare Conference to be held in Boston, Massachusetts.  Speaking at the conference on September 7th, 2011 at 3:50 PM EDT, will be the Company's Chief Executive Officer, Robert W. Musslewhite, and the Company's Chief Financial Officer, Michael T. Kirshbaum.  

(Logo: http://photos.prnewswire.com/prnh/20110802/PH45999LOGO )

The presentation materials will be available on the Company's web site, found at www.advisoryboardcompany.com through September 30, 2011.

About The Advisory Board Company

The Advisory Board Company provides best practices research and analysis, business intelligence and software tools, and management and advisory services primarily to the health care industry, focusing on business strategy, operations, and general management issues.  The Company provides best practices and research through discrete programs to a membership of approximately 3,200 organizations, including leading hospitals, health systems, pharmaceutical and biotech companies, health care insurers, medical device and supply companies, colleges, universities, and other educational institutions.  Members of each program are typically charged a fixed annual fee and have access to an integrated set of services that may include best practice research studies, executive education seminars, customized research briefs, web-based access to the program's content database, and business intelligence and software tools.

SOURCE The Advisory Board Company

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.